Know Cancer

or
forgot password

Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma


Phase 3
18 Years
75 Years
Open (Enrolling)
Both
Follicular Lymphoma

Thank you

Trial Information

Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma


Assessment of Overall Survival (OS)in patients treated with R−CVP, R−CHOP and R−FM.
−Assessment of Progression Free Survival (PFS)in patients treated with R−CVP, R−CHOP −
Assessment of Duration of Response (DR)in patients treated with R−CVP, R−CHOP and R−FM. −
Assessment of Response Rate(RR) in patients treated with R−CVP, R−CHOP and R−FM. −
Assessment of molecular Response Rate in patients treated with R−CVP, R−CHOP and R−FM. −
Assessment of toxicity of R−CVP, R−CHOP, R−FM treatments.


Inclusion Criteria:



1. Histological DIAGNOSIS of B cell follicular lymphoma

2. ECOG performance status 0−2

3. Age range 18−75

4. Ann Arbor Stage: II−IV

5. Assessment of pathology with diagnostics biopsy

6. Presence of one of these criteria:

- B Sistemic symptoms B

- Extranodale pathology

- Cytopenia

- Splenomegaly

- Leukemia

- Serous effusion

- Ves > 20 mm/h

- Ldh > normal value

- Nodale or extranodal mass > 7 cm

- 3 or more nodal sites > 3 cm

- Adenopatic syndrome

7. LVEF > 50%

8. Normal hepatic (bilirubin < 1.5 mg/dl) and renal functionality (creatinin < 2 mg/dl).
If there is a lymphoma it's allow values of bilirubin > 1.5 mg/dl and of creatinin >
2mg/dl

9. No previous treatment for follicolar lymphoma unless RT−IF

10. Lifetime > 6 mounth

11. Absence of HbsAg, HCV e HIV

12. Negative Coombs Test

13. Negative pregnant test

14. Cotracceptive method during the treatment and the follow three months

15. Formal written consent

16. Ability to follow the patients after the treatment for follow up

Exclusion Criteria:

1. Histological Diagnosis of all type of lymphoma unless Follicularlymphoma, CD20
lymphoma, stage IIIb of follicular lymphoma and high degree lymphoma

2. Stage I of Ann Arbor scale

3. Central Nervous system involvement

4. HIV, HBV OR HCV Positivity

5. Cardiac Pathology

6. Positive Coombs Test

7. Previous chemotherapeutic treatment

8. Hypersensitivity to antibodyes or other murine proteins

9. Previous cancer pathology unless in situ cervix and epithelial carcinomas

10. Other type of infections

11. Pregnant and nursing woman

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Assessment of the Time to Treatment Failure (TTF)in patients treated with R-CVP, R-CHOP and R-FM.

Outcome Time Frame:

2 years

Safety Issue:

Yes

Principal Investigator

Massimo Federico, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Azienda Ospedaliera - Universitaria di Modena

Authority:

Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Study ID:

IIL−FOLL05

NCT ID:

NCT00774826

Start Date:

December 2005

Completion Date:

March 2014

Related Keywords:

  • Follicular Lymphoma
  • Follicular lymphoma
  • Rituximab
  • Lymphoma
  • Lymphoma, Follicular

Name

Location